Ann: Quarterly Activity Report and Appendix 4C, page-21

so in your opinion, investigator led trials don’t count? Ok.
what about the 1500 patients in the historical trials that were dosed with Bisantrene, and to replicate the data in current circumstance would cost > $500M?
RAC is not your normal biotech.
So perhaps pointless comparing with others without zero patients?
With recent announcements,Even FDA likes what it sees with RC220.
Bis is still the world’s best FTO inhibitor and still the only inhibitor with cardioprotection mechanism.
I am guessing that is the reason for you as well. Agreed with you we need bit more patience, but can almost see the lighthouse.